After joining PIVI, Mongolia’s first influenza vaccination campaign prioritized healthcare workers. This campaign was highly successful, and Mongolia was able to broaden its targeted inoculation groups. Each year, the country has increased the number of vaccines purchased underscoring its commitment to building a stable program. To increase awareness of its vaccination program, Mongolia and PIVI created an animated television short that has been broadcast on five TV channels and embedded on three national websites.
Information gathering has been a fundamental part of Mongolia’s vaccination process. It hosted an advocacy meeting with key decision-makers from the Ministry of Health, the National Immunization Technical Advisory Group, the National Influenza Center of Mongolia, and the National Department of Communicable Diseases to discuss the impact of flu vaccination. Mongolia completed a national survey of Adverse Events Following Flu Immunization (AEFI), including recipients of Protein Sciences Flublok vaccine, the first recombinant protein influenza vaccine approved by the United States.
During the pandemic, COVID-19 planning and deployment was supported by the existing influenza vaccine system. PIVI tailored its tools to support health worker training and education, the creation of vaccine communication materials for the general public, as well as support with Adverse Event Following Immunization (AEFI) monitoring.
KAP Study on Pregnant Women and HCWs
Analysis of birth outcomes and adverse events in vaccinated pregnant women
Economic burden of flu study
Cost-effectiveness analysis of flu vaccination